Grants rights to research, develop and commercialize antibodies generated using the AlivaMab Mouse platform
SAN DIEGO, Calif. – Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, today announced a license agreement with Allogene Therapeutics, Inc. The license grants Allogene rights to research, develop and commercialize certain AlivaMab antibodies against several targets. Financial terms were not disclosed.
“Ablexis is excited to add Allogene Therapeutics, a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, as a licensee,” said Larry Green, Ph.D., Chief Executive Officer of Ablexis. “This agreement with Allogene highlights the potential applications of AlivaMab antibodies in novel drug modalities such as CAR Ts. We believe our transgenic mouse platform will play an integral role in the continued advancement of the field of immunotherapy.”
The AlivaMab Mouse is designed to enable and optimize the efficient discovery and development of the next generation of human therapeutic antibodies. The platform has been validated for antibody drug discovery by Ablexis and partners in various formats including regular antibodies, bispecifics and CAR Ts and for a range of applications.
